Case Report: Deficiency of Adenosine Deaminase 2 Presenting With Overlapping Features of Autoimmune Lymphoproliferative Syndrome and Bone Marrow Failure.
Adenosine Deaminase
/ deficiency
Adrenal Cortex Hormones
/ therapeutic use
Anemia, Hemolytic, Autoimmune
/ genetics
Autoimmune Lymphoproliferative Syndrome
/ genetics
Blood Component Transfusion
Bone Marrow Failure Disorders
/ genetics
Child, Preschool
Combined Modality Therapy
Delayed Diagnosis
Fatal Outcome
Genes, Recessive
Genetic Association Studies
High-Throughput Nucleotide Sequencing
Humans
Immunosuppressive Agents
/ therapeutic use
Intercellular Signaling Peptides and Proteins
/ deficiency
Iron Chelating Agents
/ therapeutic use
Multiple Organ Failure
/ etiology
Mutation, Missense
Pedigree
Pulmonary Embolism
/ etiology
Purpura, Thrombocytopenic, Idiopathic
/ genetics
STAT3 Transcription Factor
/ genetics
Splenectomy
Symptom Assessment
DADA2
autoimmune lymphoproliferative syndrome (ALPS)
bone marrow failure (BMF)
inborn errors of immunity (IEI)
next-generation sequencing (NGS)
primary immune regulatory disorders (PIRDS)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
08
2021
accepted:
23
09
2021
entrez:
1
11
2021
pubmed:
2
11
2021
medline:
12
2
2022
Statut:
epublish
Résumé
Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disease associated with a highly variable clinical presentation, such as vasculitis, inflammation, and hematologic manifestations. Some associations of clinical features can mimic autoimmune lymphoproliferative syndrome (ALPS). We report a case of a female patient who fulfilled the 2009 National Institute of Health revised criteria for ALPS and received a delayed diagnosis of DADA2. During her childhood, she suffered from autoimmune hemolytic anemia, immune thrombocytopenia, and chronic lymphoproliferation, which partially responded to multiple lines of treatments and were followed, at 25 years of age, by pulmonary embolism, septic shock, and bone marrow failure with myelodysplastic evolution. The patient died from the progression of pulmonary disease and multiorgan failure. Two previously unreported variants of gene ADA2/CECR1 were found through next-generation sequencing analysis, and a pathogenic role was demonstrated through a functional study. A single somatic STAT3 mutation was also found. Clinical phenotypes encompassing immune dysregulation and marrow failure should be evaluated at the early stage of diagnostic work-up with an extended molecular evaluation. A correct genetic diagnosis may lead to a precision medicine approach consisting of the use of targeted treatments or early hematopoietic stem cell transplantation.
Identifiants
pubmed: 34721429
doi: 10.3389/fimmu.2021.754029
pmc: PMC8552009
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Immunosuppressive Agents
0
Intercellular Signaling Peptides and Proteins
0
Iron Chelating Agents
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
ADA2 protein, human
EC 3.5.4.4
Adenosine Deaminase
EC 3.5.4.4
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
754029Informations de copyright
Copyright © 2021 Dell’Orso, Grossi, Penco, Caorsi, Palmisani, Terranova, Schena, Lupia, Ricci, Montalto, Pierri, Ceccherini, Fioredda, Dufour, Gattorno and Miano.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
Références
Blood. 2013 Oct 3;122(14):2453-9
pubmed: 23926297
Eur J Immunol. 1998 Feb;28(2):540-7
pubmed: 9521064
Comp Biochem Physiol B Biochem Mol Biol. 2004 Feb;137(2):247-54
pubmed: 14990221
J Clin Immunol. 2018 Feb;38(2):166-173
pubmed: 29411230
Clin Immunol. 2001 Sep;100(3):314-24
pubmed: 11513545
Cell Mol Life Sci. 2017 Feb;74(3):555-570
pubmed: 27663683
J Pediatr Hematol Oncol. 2020 Nov;42(8):e768-e771
pubmed: 31876783
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1970-1985.e4
pubmed: 30877075
Front Pediatr. 2018 Oct 18;6:282
pubmed: 30406060
J Allergy Clin Immunol. 2020 Jun;145(6):1664-1672.e10
pubmed: 31945408
Biosci Rep. 1982 May;2(5):303-14
pubmed: 6980023
N Engl J Med. 2004 Sep 30;351(14):1409-18
pubmed: 15459302
J Allergy Clin Immunol. 2018 Apr;141(4):1534-1537.e8
pubmed: 29391253
Rheumatology (Oxford). 2016 May;55(5):902-10
pubmed: 26867732
J Rheumatol. 2015 Aug;42(8):1532-4
pubmed: 26233953
J Clin Immunol. 2018 Jul;38(5):569-578
pubmed: 29951947
Rheumatology (Oxford). 2021 Apr 28;:
pubmed: 33909886
F1000Res. 2017 Nov 1;6:1928
pubmed: 29123652
N Engl J Med. 2014 Mar 6;370(10):921-31
pubmed: 24552285
Pediatr Blood Cancer. 2018 Apr;65(4):
pubmed: 29271561
J Allergy Clin Immunol. 2016 Aug;138(2):628-630.e2
pubmed: 27130863
N Engl J Med. 2012 May 17;366(20):1905-13
pubmed: 22591296
Blood. 2017 Dec 14;130(24):2682-2688
pubmed: 28974505
Immunity. 2012 Apr 20;36(4):515-28
pubmed: 22520845
J Leukoc Biol. 2010 Aug;88(2):279-90
pubmed: 20453107
J Exp Med. 2021 Feb 1;218(2):
pubmed: 33170215
J Allergy Clin Immunol. 2015 Jan;135(1):283-7.e5
pubmed: 25457153
J Pediatr Hematol Oncol. 2021 Nov 1;43(8):e1168-e1172
pubmed: 33625086
J Allergy Clin Immunol Pract. 2020 Jan;8(1):273-282
pubmed: 31377437
Br J Haematol. 2019 Nov;187(4):502-508
pubmed: 31309545
N Engl J Med. 2014 Jul 31;371(5):480
pubmed: 25075848
Blood. 2016 Jul 14;128(2):227-38
pubmed: 27099149
Front Pediatr. 2021 Mar 18;9:624116
pubmed: 33816397
Bone Marrow Transplant. 1998 Apr;21 Suppl 2:S37-41
pubmed: 9630323
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Biol Chem. 2006 Mar;387(3):319-21
pubmed: 16542154
J Allergy Clin Immunol. 2018 Oct;142(4):1363-1365.e8
pubmed: 29936104
N Engl J Med. 2007 Oct 18;357(16):1608-19
pubmed: 17881745
Am J Hematol. 2021 Sep 1;96(9):1077-1086
pubmed: 34000087
Biochem J. 2005 Oct 1;391(Pt 1):51-7
pubmed: 15926889
Ann Rheum Dis. 2017 Oct;76(10):1648-1656
pubmed: 28522451
Genes (Basel). 2021 Aug 24;12(9):
pubmed: 34573280
Blood. 2010 Oct 7;116(14):e35-40
pubmed: 20538792
Br J Haematol. 2019 Mar;184(5):861-864
pubmed: 29527658
J Clin Immunol. 2018 Jul;38(5):558-568
pubmed: 29911256
N Engl J Med. 2014 Jul 31;371(5):478
pubmed: 25075845
N Engl J Med. 2014 Mar 6;370(10):911-20
pubmed: 24552284